Tag
The SUPER-FIN randomized trial reveals that cast immobilization is a viable, non-inferior alternative to surgery for unstable Weber B ankle fractures with a congruent mortise, leading to fewer complications and avoiding unnecessary hardware
The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int
A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting th
A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction
A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.
The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi
This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise
A rigorous clinical trial reveals that five weeks of resveratrol supplementation does not improve blood sugar, GLP-1 levels, or gastric emptying in patients with type 2 diabetes.
The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.
A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.
A multi-center randomized clinical trial involving 257 youths found that adjunctive omega-3 fatty acids (1.5 g/d) did not outperform placebo in treating moderate-to-severe pediatric major depressive disorder, despite high adherence and conc
The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man
CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.
A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su
The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves’ hy
A large, rigorous study found that sertraline, an antidepressant, does not significantly lower the risk of repeated violent crimes among impulsive offenders.
The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant
This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity,
The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive dec
